HomeCompareIMRNW vs PLD

IMRNW vs PLD: Dividend Comparison 2026

IMRNW yields 2339.18% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMRNW wins by $43075570627.45M in total portfolio value
10 years
IMRNW
IMRNW
● Live price
2339.18%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43075570633.35M
Annual income
$39,734,102,642,272,360.00
Full IMRNW calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — IMRNW vs PLD

📍 IMRNW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMRNWPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMRNW + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMRNW pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMRNW
Annual income on $10K today (after 15% tax)
$198,830.41/yr
After 10yr DRIP, annual income (after tax)
$33,773,987,245,931,504.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, IMRNW beats the other by $33,773,987,241,893,388.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMRNW + PLD for your $10,000?

IMRNW: 50%PLD: 50%
100% PLD50/50100% IMRNW
Portfolio after 10yr
$21537785319.63M
Annual income
$19,867,051,323,511,544.00/yr
Blended yield
92.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

IMRNW
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMRNW buys
0
PLD buys
0
No recent congressional trades found for IMRNW or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMRNWPLD
Forward yield2339.18%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$43075570633.35M$5.91M
Annual income after 10y$39,734,102,642,272,360.00$4,750,725.19
Total dividends collected$42841070616.16M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IMRNW vs PLD ($10,000, DRIP)

YearIMRNW PortfolioIMRNW Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$244,618$233,918.13$11,241$540.96+$233.4KIMRNW
2$5,609,462$5,347,721.02$13,019$991.13+$5.60MIMRNW
3$120,610,820$114,608,695.17$15,801$1,870.97+$120.60MIMRNW
4$2,432,079,455$2,303,025,877.36$20,609$3,701.21+$2432.06MIMRNW
5$46,004,003,878$43,401,678,861.20$29,919$7,867.97+$46003.97MIMRNW
6$816,480,868,143$767,256,583,993.93$50,631$18,617.74+$816480.82MIMRNW
7$13,600,083,122,647$12,726,448,593,733.79$105,528$51,352.20+$13600083.02MIMRNW
8$212,667,837,578,363$198,115,748,637,130.90$287,364$174,449.42+$212667837.29MIMRNW
9$3,122,867,281,384,664$2,895,312,695,175,815.50$1,081,760$774,280.77+$3122867280.30MIMRNW
10$43,075,570,633,353,950$39,734,102,642,272,360.00$5,908,209$4,750,725.19+$43075570627.45MIMRNW

IMRNW vs PLD: Complete Analysis 2026

IMRNWStock

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers’ diarrhea in the United States, and Travelers’ Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Full IMRNW Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this IMRNW vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMRNW vs SCHDIMRNW vs JEPIIMRNW vs OIMRNW vs KOIMRNW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.